PMID- 37565322
OWN - NLM
STAT- MEDLINE
DCOM- 20240130
LR  - 20240422
IS  - 1552-4604 (Electronic)
IS  - 0091-2700 (Linking)
VI  - 64
IP  - 2
DP  - 2024 Feb
TI  - Real-World Experience With Deutetrabenazine for Huntington Disease Chorea.
PG  - 178-181
LID - 10.1002/jcph.2336 [doi]
AB  - Huntington disease (HD) is a hereditary neurodegenerative disorder with a 
      hallmark feature of chorea. While no disease-modifying therapies currently exist 
      for HD, symptomatic treatment of HD-associated chorea includes US Food and Drug 
      Administration-approved vesicular monoamine transporter type 2 
      inhibitors-tetrabenazine and deutetrabenazine. Deutetrabenazine was more recently 
      approved (2017), and while structurally similar to tetrabenazine, 
      deutetrabenazine has a unique pharmacokinetic profile that allows for a longer 
      half-life, reduced plasma fluctuations, and less frequent dosing. In pivotal 
      trials, deutetrabenazine seemed to have an improved safety and tolerability 
      profile over tetrabenazine but real-world data to confirm this are lacking. Here, 
      we evaluate our real-world clinical experience with deutetrabenazine for 
      HD-associated chorea. We performed a retrospective chart review of all patients 
      with HD who initiated treatment with deutetrabenazine from January 2017 to May 
      2019 at the University of Alabama at Birmingham. Total maximal chorea scores, 
      patient-reported subjective efficacy, dosing information, and subjective reports 
      of adverse events (AEs) were abstracted for each patient. Our review included 58 
      patients with a mean length of treatment of 476.4 days. In the reviewed time 
      period, the mean treatment difference in total maximal chorea scores was 4.4. The 
      combined total rate of occurrence of any AEs was relatively low, at 32.8%, and 
      the most commonly reported AEs were sedation (15.5%), insomnia (6.9%), and 
      diarrhea (3.4%). Our real-world data support current literature indicating that 
      deutetrabenazine is an effective and well-tolerated treatment for HD-associated 
      chorea. Further studies repeating this on a larger scale, across a greater 
      geography and practice pattern, are needed.
CI  - (c) 2023, The American College of Clinical Pharmacology.
FAU - Curtis, Kendall
AU  - Curtis K
AUID- ORCID: 0000-0002-2450-636X
AD  - University of Pittsburgh School of Medicine, Pittsburgh, PA, USA.
AD  - Department of Neurology, Division of Movement Disorders, University of Alabama at 
      Birmingham, Birmingham, Alabama, USA.
FAU - Sung, Victor
AU  - Sung V
AD  - Department of Neurology, Division of Movement Disorders, University of Alabama at 
      Birmingham, Birmingham, Alabama, USA.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20230824
PL  - England
TA  - J Clin Pharmacol
JT  - Journal of clinical pharmacology
JID - 0366372
RN  - P341G6W9NB (deutetrabenazine)
RN  - Z9O08YRN8O (Tetrabenazine)
RN  - 0 (Adrenergic Uptake Inhibitors)
SB  - IM
MH  - Humans
MH  - *Huntington Disease/drug therapy
MH  - *Chorea/drug therapy/chemically induced
MH  - Tetrabenazine/adverse effects
MH  - Retrospective Studies
MH  - Adrenergic Uptake Inhibitors/adverse effects
OTO - NOTNLM
OT  - Huntington disease
OT  - chorea
OT  - deutetrabenazine
OT  - movement disorders
OT  - tetrabenazine
EDAT- 2023/08/11 06:42
MHDA- 2024/01/30 12:43
CRDT- 2023/08/11 05:27
PHST- 2023/07/03 00:00 [received]
PHST- 2023/08/09 00:00 [accepted]
PHST- 2024/01/30 12:43 [medline]
PHST- 2023/08/11 06:42 [pubmed]
PHST- 2023/08/11 05:27 [entrez]
AID - 10.1002/jcph.2336 [doi]
PST - ppublish
SO  - J Clin Pharmacol. 2024 Feb;64(2):178-181. doi: 10.1002/jcph.2336. Epub 2023 Aug 
      24.